Calliditas Therapeutics-ADRCALT
13F holders, Q3 2024 (September 30)5holders −13
3new positions
17sold out
$36.94avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Calliditas Therapeutics-ADR (CALT) in their 13F filings, down 13 from Q2 2024. 3 opened new positions and 17 sold out. The largest holders were Crossmark Global Holdings, Inc. ($655K), Advisors Preferred, LLC ($82K) and Rhumbline Advisers ($12K).
- Company
- Calliditas Therapeutics-ADR
- CUSIP
- 13124Q106
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $737K |
| Exits | 17 | $32.3M |
All 13F filers, Q2 2024 → Q3 2024: 20,066 shares bought and 825,084 shares sold, net −805,018 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Crossmark Global Holdings, Inc. | 0.01% | New | 16,117 | $655K |
| Advisors Preferred, LLC | 0.01% | New | 2,022 | $82K |
| Rhumbline Advisers | 0.00% | Add +50.0% | 303 | $12K |
| Missouri Trust & Investment Co | 0.00% | No change | 35 | $1K |
| Simplex Trading, LLC | 0.00% | New | 1,826 | $0 |
"% of holder's portfolio" is CALT's weight in each manager's 13F, not the share of Calliditas Therapeutics-ADR the manager owns.